Clinical Trial

An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).

Study acronym: PALACE3
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Patients with locally advanced esophageal squamous cell carcinoma will randomly assigned to receive neoadjuvant chemo-radiotherapy combined with immunotherapy post organ preservation strategy (experimental group) or neoadjuvant chemo-radiotherapy followed by surgery (control group). The 3-year overall survival rate is the primary outcome.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-29.
Status change: Not Yet Recruiting → Recruiting 2024-06-30
Trial Details
NCT Number NCT06339060
Lead Sponsor Ruijin Hospital
Conditions Esophageal Cancer
Enrollment 356 participants
Start Date 2024-05-01
Primary Completion 2028-03-01 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2024-07-03